Inovio Pharmaceuticals (NASDAQ:INO) versus Nephros (NASDAQ:NEPH) head-to-head contrast


Nephros (NASDAQ:NEPH – Get Rating) and Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) are both small medical companies, but which is the better investment? We’ll compare the two companies based on their dividend strength, analyst ratings, valuation, profitability, institutional ownership, risk and reward.

Analyst Recommendations

This is a breakdown of the current ratings for Nephros and Inovio Pharmaceuticals as provided by MarketBeat.

sell reviews keep ratings Buy reviews Strong buy recommendations rating score
nephros 0 1 2 0 2.67
Inovio Pharmaceuticals 0 5 0 0 2.00

Nephros currently has a consensus price target of $11.42, indicating a potential upside of 456.91%. Inovio Pharmaceuticals has a consensus price target of $11.80, indicating a potential upside of 492.96%. Given Inovio Pharmaceuticals’ more likely upside potential, analysts clearly believe Inovio Pharmaceuticals is cheaper than Nephros.

risk and volatility

Nephros has a beta of 1.23, meaning its stock price is 23% more volatile than the S&P 500. In comparison, Inovio Pharmaceuticals has a beta of 0.8, meaning its stock price is 20% less volatile than the S&P 500 S&P 500.

Insider and Institutional Property

55.6% of Nephros shares are held by institutional investors. In comparison, 43.3% of shares in Inovio Pharmaceuticals are held by institutional investors. 8.6% of Nephros shares are held by insiders. In comparison, 3.3% of shares in Inovio Pharmaceuticals are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds, and large wealth managers believe a company is poised for long-term growth.

Score & Rating

This table compares the revenue, earnings per share, and valuation of Nephros and Inovio Pharmaceuticals.

gross receipts price/sales ratio net income earnings per share price-earnings ratio
nephros $10.40 million 2.03 -$4.11 million ($0.55) -3.73
Inovio Pharmaceuticals $1.77 million 257.51 -$303.66 million ($1.54) -1.29

Nephros has higher sales and earnings than Inovio Pharmaceuticals. Nephros is trading at a lower price-to-earnings multiple than Inovio Pharmaceuticals, suggesting it’s the cheaper of the two stocks at the moment.


This table compares the net margins, return on equity and return on assets for Nephros and Inovio Pharmaceuticals.

net margins return on equity return on investment
nephros -53.75% -36.24% -30.71%
Inovio Pharmaceuticals -20,479.29% -76.48% -63.47%


Nephros beats Inovio Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

About Nephros (received rating)

Nephros, Inc. develops and markets high-performance water solutions for the medical and commercial markets throughout the United States. The Company operates through three segments: Water Filtration, Pathogen Detection and Kidney Products. It offers ultrafiltration products used in dialysis centers to remove biological contaminants from water and bicarbonate concentrates; and in hospitals to prevent infection from waterborne pathogens such as Legionella and Pseudomonas, as well as in military and outdoor recreational, commercial and other healthcare facilities. The Company also develops and sells real-time water testing systems to provide actionable data on aquatic pathogens; and medical devices for patients with renal disease, including a second-generation hemodiafiltration system for the treatment of patients with end-stage renal disease. It also offers water filters that improve water taste and odor, as well as reduce biofilm, bacteria and scale build-up in downstream equipment under the Nephros and AETHER brands for the hospitality, hospitality, grocery store and healthcare markets. The company was founded in 1997 and is headquartered in South Orange, New Jersey.

About Inovio Pharmaceuticals (received rating)

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc., a biotechnology company, is focused on the discovery, development and commercialization of DNA drugs to treat and protect people from human papillomavirus (HPV)-related diseases, cancer and infectious diseases. Its DNA drug platform uses precisely engineered SynCon that identifies and optimizes the DNA sequence of the target antigen and CELLECTRA Smart Devices technology that facilitates the delivery of the DNA plasmids. The Company is engaged in conducting and planning clinical trials of its DNA medicines for HPV-associated pre-cancers, including cervical, vulvar and anal dysplasia; HPV-associated cancers such as head and neck, cervical, anal, penile, vulva, and vaginal cancer; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East respiratory syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense ( DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research and The Wistar Institute. The Company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support the investigational DNA vaccine INO-4800 for COVID-19; and a partnership with the International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Receive news and reviews for Nephros Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Nephros and related companies with’s FREE daily email newsletter.


Comments are closed.